Form 4: Director Jason Haas Executes Stock Options at Ligand

Director Jason Haas exercised stock options and sold shares of Ligand Pharmaceuticals Inc. on June 12, 2026.

Summary

• Director Jason Haas exercised options for 4,000 shares of Ligand Pharmaceuticals common stock at an exercise price of $51.56.
• Following the exercise, the director sold a total of 6,461 shares in multiple transactions.
• The sales occurred at weighted-average prices of $255.0113 and $256.0781 per share.
• The reporting person's direct beneficial ownership of common stock stands at 4,981 shares following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents routine insider activity rather than a strategic shift or financial distress.

Positives

• The director maintains a remaining direct ownership of 4,981 shares, indicating continued alignment with the company.

Negatives

• The transaction represents a net reduction in the director's direct shareholding position.

Risks

• None mentioned in this filing.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that director stock sales are common occurrences for liquidity or tax planning purposes and do not necessarily reflect a change in the company's fundamental outlook.

Comparison to Industry Standards

• The transaction follows standard regulatory disclosure requirements for corporate insiders under Section 16(a) of the Securities Exchange Act.

Stakeholder Impact

• Minimal impact expected as this is a standard insider transaction.

Next Steps

• No future actions or milestones mentioned.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Insider Trading, Form 4, Stock Options, Director Transaction